Kashiv BioSciences
Focus: Kashiv BioSciences is a newly-founded (2024) biosimilar company headquartered in New Jersey with commercial-stage assets in infectious disease and supportive care. The company is currently generating 100% of revenue from FYLNETRA (pegfilgrastim biosimilar).
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Open Jobs
29-3 this month
Stable — net -3 jobs in 30d
14 added, 17 removed. Backfill posture.
Should You Work at Kashiv BioSciences?
AI assessmentKashiv offers exciting early-stage growth potential and manufacturing-focused hiring, but extreme revenue concentration and early-stage pipeline pose material career risk for those seeking stability.
Why Work Here
- Pure-play biosimilar developer with two approved products (FYLNETRA, RELEUKO) already at peak lifecycle stages, offering immediate commercial relevance.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$81K Part DStable
Peak
Only approved revenue-generating product; acts as a colony-stimulating factor to stimulate proliferation and differentiation of hematopoietic cells.
Help build intelligence for Kashiv BioSciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.